JENA, Germany—Carl Zeiss Meditec generated revenue of €855.4 million in the first six months of the fiscal year ending March 31, 2022 versus €767.4 million the prior year, an 11.5 percent increase compared with the same period of the prior year (+10.7 percent adjusted for currency effects). Order intake rose to an even greater extent than revenue, climbing 30.7 percent to €1,062.3 million versus €812.9 million the prior year. Earnings before interest and taxes (EBIT) increased slightly to €177.3 million. The EBIT margin was 20.7 percent compared with 21.2 percent the prior year. The adjusted EBIT margin amounted to 21.2 percent compared with 21.4 percent the prior year, which approximates the previous year’s figure.

“The supply chain situation in the equipment business has deteriorated further in the past few months—due, among other things, to the war in Ukraine and the COVID-19 lockdowns in China,” said Dr. Markus Weber, member of the executive board of the Zeiss Group and head of the company’s medical technology segment. “I am therefore all the more delighted to be reporting these good half-year results—an outstanding team achievement.”
 
Revenue in the strategic business unit (SBU) Ophthalmic Devices increased by 10.5 percent in the first six months of fiscal year 2021/22 (+9.7 percent adjusted for currency effects) to €651.9 million versus €590.1 million the prior year. Recurring revenue from consumables, implants and services once again contributed significantly to growth, Zeiss said.
 
Zeiss noted that its equipment business is impacted by supply chain bottlenecks. As a result, order intake in the Ophthalmic Devices SBU increased disproportionately to revenue. Revenue in the Microsurgery SBU increased by 14.8 percent (+13.8 percent adjusted for currency effects) to €203.5 million versus €177.3 million the prior year. Order intake in the Microsurgery SBU likewise increased at a much higher rate than revenue.
 
Revenue in the EMEA region increased by 5.8 percent (+7.1 percent adjusted for currency effects) to €229.2 million, compared with €216.7 million the prior year. Order intake in core European markets exhibited a positive trend, Zeiss said.
 
Revenue in the Americas region increased by 7.6 percent (+2.6 percent adjusted for currency effects) to €212.2 million, compared with €197.2 million the prior year. Zeiss cited the stable development in the U.S. as well as a further recovery in the countries of South America as factors that contributed to the growth.
 
In the APAC region, revenue increased to €414.1 million, compared with €353.5m in the prior year (+17.1 percent; adjusted for currency effects). The strongest contributions to growth came from China and India, Zeiss said, adding that the Japanese market also recorded growth.
 
Zeiss said its outlook for fiscal year 2021/22 remains unchanged, with revenue expected to grow at least to the same extent as the market.